

# Clinical Policy: Nerve Blocks and Neurolysis for Pain Management

Reference Number: LA.CP.MP.170

Date of Last Revision: 04/26

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

## Description

Nerve blocks are the temporary interruption of conduction of impulses in peripheral nerves or nerve trunks created by the injection of local anesthetic solutions. They can be used to identify the source of pain or to treat pain.

## Note:

- For sacroiliac nerve block and radiofrequency neurotomy, please refer to LA.CP.MP.166 Sacroiliac Joint Interventions.
- For facet joint injections and radiofrequency neurotomy, please refer to LA.CP.MP.171 Facet Joint Interventions

## Policy/Criteria

It is the policy of Louisiana Healthcare Connections that invasive pain management procedures performed by a physician are **medically necessary** when *the relevant criteria are met, and the patient receives only one procedure per visit; with or without radiographic guidance.*

## Table of Contents

|                                                                              |   |
|------------------------------------------------------------------------------|---|
| I. Occipital Nerve Block.....                                                | 1 |
| II. Sympathetic Nerve Blocks.....                                            | 2 |
| III. Celiac Plexus Nerve Block/Neurolysis.....                               | 3 |
| IV. Intercostal Nerve Block/Neurolysis .....                                 | 3 |
| V. Genicular Nerve Blocks and Genicular Nerve Radiofrequency Neurotomy ..... | 3 |
| VI. Peripheral/Ganglion Nerve Blocks .....                                   | 4 |
| VII. Intraosseous Radiofrequency Nerve Ablation of Basivertebral Nerve.....  | 4 |

## I. Occipital Nerve Block

A. *An initial injection* of a local anesthetic for the diagnosis of suspected occipital neuralgia is **medically necessary** when all of the following are met:

1. Patient has unilateral or bilateral pain located in the distribution of the greater, lesser and/or third occipital nerves<sup>1</sup>;
2. Pain has at least two of the following three characteristics<sup>1</sup>:
  - a. Recurring in paroxysmal attacks lasting from a few seconds to minutes;
  - b. Severe intensity;
  - c. Shooting, stabbing, or sharp in quality;
3. Pain is associated with dysesthesia and/or allodynia apparent during innocuous stimulation of the scalp and/or hair, and at least one of the following<sup>1</sup>:

- a. Tenderness over the affected nerve branches;
  - b. Trigger point at the emergence of the greater occipital nerve or in the distribution of C2.
- B. *Therapeutic occipital nerve blocks* are **medically necessary** when all of the following are met:
1. There was temporary relief from the initial/previous injection as evidenced by a reduction in numeric rating scale pain score reported by the member/enrollee;
  2. The member/enrollee has failed three months of conservative treatment including all of the following:
    - a. Heat, rest and/or physical therapy, including massage;
    - b. NSAIDS, unless contraindicated or not tolerated;
    - c. Oral anticonvulsant medications (e.g., carbamazepine, gabapentin, pregabalin) or tricyclic antidepressants;
    - d. Activity modification to address triggers;
  3. No more than four injections are to be given within 12 months (includes diagnostic injection).
- C. *Occipital nerve block* for the diagnosis or treatment of other types of headaches, including migraine and cervicogenic headaches, is considered **not medically necessary** as effectiveness has not been established.

*Note: Please refer to LA.CP.PHAR.232 OnabotulinumtoxinA (Botox) for requests for Botox injections for migraines.*

**II. Sympathetic Nerve Blocks** have limited evidence to prove effectiveness of treatment and consideration will be made on a case-by-case basis. The criteria below provide a basis for documenting patient-specific clinical information to help guide clinical decision making.

- A. *First or second sympathetic nerve block*:
1. Diagnosis of *complex regional pain syndrome* (CRPS) (also called reflex sympathetic dystrophy) and all of the following:
    - a. Pain is being managed by a pain management specialist with experience treating CRPS;
    - b. The member/enrollee is in an active rehabilitation regimen;
    - c. Failed  $\geq$  three weeks of conservative therapies such as activity modification, exercises, topical application of lidocaine or capsaicin cream, and oral medical management such as nonsteroidal anti-inflammatories, antidepressants, anticonvulsants, and glucocorticoids;
    - d. Two or more of the following findings of the involved digit/extremity:
      - i. Hyperalgesia or allodynia (pain sensation in response to a typically non-painful stimulus);
      - ii. Evidence of edema and/or sweating changes and/or sweating asymmetry;
      - iii. Evidence of temperature asymmetry ( $>1^{\circ}\text{C}$ ) and/or skin color changes and/or asymmetry;

- iv. Evidence of decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nails, skin).
- B. *Additional sympathetic nerve blocks for CRPS may be considered medically necessary when all of the following are met:*
  - 1. Nerve blocks are given at least one week apart;
  - 2. There was an immediate positive response to the first or second nerve block (e.g., improved temperature of  $\geq 1.5^{\circ}\text{C}$  and decreased pain).
- C. *Additional sympathetic nerve blocks without documented benefit from the first or second are **not medically necessary**.*
- D. Sympathetic nerve blocks for any other indication, including ischemic limb pain, are **not medically necessary** as there is a lack of evidence to support effectiveness.

### III. Celiac Plexus Nerve Block/Neurolysis

- A. *Celiac plexus nerve block/neurolysis is **medically necessary** for either of the following indications:*
  - 1. Chronic neuralgic pain secondary to pancreatic cancer, all of the following:
    - a. Diagnosis of pancreatic cancer with severe visceral abdominal/back pain;
    - b. Strong analgesics such as opioids are no longer effective, or their side effects decrease quality of life;
    - c. No malignancy in an area of somatic innervation such as the peritoneum or diaphragm.
  - 2. Refractory pain due to chronic pancreatitis with non-dilated pancreatic duct.<sup>30,40</sup>
- B. A repeat *celiac plexus nerve block* for refractory pain from chronic pancreatitis with non-dilated pancreatic duct is **medically necessary** when both of the following are met:
  - 1. At least three months have passed since previous injection;
  - 2. There was a clinical benefit from the initial celiac block (e.g., alleviation or reduction of abdominal pain, elimination of the need for oral analgesia).
- C. *Repeat celiac plexus nerve blocks or neurolysis, for any indication other than those noted above, are **not medically necessary** as there is a lack of evidence to support effectiveness.*

### IV. Intercostal Nerve Block/Neurolysis

- A. *Intercostal nerve block/neurolysis is **medically necessary** for chronic neuralgic pain secondary to an injured intercostal nerve as a result of a rib fracture, a thoracotomy incision or chronic pain due to post herpetic neuralgia, or other neuropathic process when all of the following are met:*
  - 1. Suspected organic problem;
  - 2. Non-responsiveness to conservative modalities of treatment;
  - 3. Pain and disability of moderate to severe degree;
  - 4. No evidence of contraindications such as infection or pain of predominately psychogenic origin.

### V. Genicular Nerve Blocks, Neurolysis and Genicular Nerve Radiofrequency Neurotomy

There is insufficient evidence to determine safety and effectiveness of *genicular nerve blocks, neurolysis and radiofrequency neurotomy of the articular nerve*.<sup>9,40</sup>

## VI. Peripheral/Ganglion Nerve Blocks

**Note:** *If administered as part of a surgery or other procedure, coding for peripheral/ganglion nerve blocks should follow proper coding practices and would not be subject to prior authorization or payment separately from the procedure.*

- A. *Peripheral nerve blocks for diagnosis and treatment of malignant pain* are considered **medically necessary** as part of a comprehensive pain management program.
- B. *Peripheral nerve blocks for diagnosis or treatment of post-herniorrhaphy pain* are considered **medically necessary** when all of the following criteria are met:
  - 1. A first diagnostic peripheral nerve block when all of the following are met:
    - a. Diagnosis of post-herniorrhaphy neuralgia;
    - b. Groin pain has persisted for three months after surgical hernia repair;
    - c. Less invasive pain management methods such as NSAIDs and/or opiates have not relieved the pain;
    - d. Imaging studies have ruled out non-neuropathic causes of pain;
    - e. Documentation indicates that pain is not attributable to any other cause;
  - 2. Therapeutic peripheral nerve block(s) for treatment of post-herniorrhaphy pain when all of the following are met:
    - a. There was temporary relief from the initial/previous injection;
    - b. Injections are given at least one week apart.
- C. *Peripheral nerve blocks for prevention or treatment of headaches*, including, but not limited to: migraine headaches, treatment-refractory migraines in pregnancy, and short-lasting unilateral neuralgiform headaches, are considered **not medically necessary** as effectiveness has not been established.
- D. There is insufficient evidence in the published peer-reviewed literature to support the use of *peripheral nerve blocks for the treatment of trigeminal neuralgia*.
- E. There is insufficient evidence in the published peer-reviewed literature to support the use of *peripheral/ganglion nerve blocks or neurolysis* for any condition not indicated elsewhere in this policy, including chronic pain. There is ongoing research but insufficient evidence to establish efficacy.

## VII. Intraosseous Radiofrequency Nerve Ablation of the Basivertebral Nerve

There is insufficient evidence to determine the safety and effectiveness of *intraosseous radiofrequency nerve ablation of the basivertebral nerve* (e.g., Intracept® Intraosseous Nerve Ablation System) for the treatment of chronic low back pain.<sup>44</sup>

## Background

*Local Injections for Cervicogenic Headache and Occipital Neuralgia*

Greater occipital nerve blocks have been advocated as a diagnostic test for cervicogenic headache and occipital neuralgia. The effectiveness of greater occipital nerve block in patients with primary headache syndromes is controversial.<sup>25</sup> The International Headache Society (IHS) defines occipital neuralgia as unilateral or bilateral paroxysmal, shooting or stabbing pain in the posterior part of the scalp, in the distribution of the greater, lesser or third occipital nerves, sometimes accompanied by diminished sensation or dysesthesia in the affected area and commonly associated with tenderness over the involved nerve(s).<sup>1</sup> The IHS includes relief of pain following a local anesthetic block of the affected nerve as part of their diagnostic criteria for occipital neuralgia.<sup>1</sup> Thus, the principal indication for occipital block is diagnosis. Another indication is the treatment of chronic occipital neuralgia, often with a series of therapeutic blocks combining local anesthetic and corticosteroid. Pain relief is typically prompt with improvement primarily noted to the sharp but not the dull component of the occipital neuralgia pain.<sup>54</sup> The pain relief may last several weeks or even months.<sup>1</sup> At that time the injection may be repeated.<sup>19,25</sup> The Veterans Affairs/Department of Defense (VA/DoD) also suggest greater occipital nerve block for the acute treatment of migraine in the VA/DoD Clinical Practice Guideline for the Primary Care Management of Headache.<sup>58</sup>

### *Sympathetic Nerve Blocks*

Sympathetic nerves may be injected for several reasons:

- Diagnostic - to determine the source of pain, e.g., to identify or pinpoint a nerve that acts as a pathway for pain; to determine the type of nerve that conducts the pain; to distinguish between pain that is central (within the spinal cord) or peripheral (outside the spinal cord) in origin; or to determine whether a neurolytic block or surgical lysis of the nerve should be performed;
- Therapeutic - to treat painful conditions that respond to nerve blocks (e.g., celiac block for pain of pancreatic cancer); and
- Prognostic - to predict the outcome of long-lasting interventions (e.g., lumbar sympathectomy).

The response to sympathetic blockade is the best diagnostic test for complex regional pain syndrome (CRPS). If the patient has had a technically successful sympathetic block and does not obtain significant relief, then the patient probably does not have CRPS. Over two-thirds of patients will obtain significant relief with minimal effect on motor and sensory function because the sympathetic fibers are the least myelinated (as compared to motor and sensory nerve fibers) and are the first to be affected by the local anesthetic.

A 2014 case report and literature review identified only five cases, and no Level I or II evidence-based trials to support the use of sympathetic nerve block for ischemic pain.<sup>16</sup> The authors presented two cases of patients who experienced severe pain due to ischemia despite full regional nerve blocks.<sup>16</sup> The available literature is not sufficient to support the use of sympathetic nerve blocks for ischemic limb pain.

### *Celiac Plexus Nerve Block/Neurolysis for Pancreatic Cancer*

Although its analgesic effectiveness is similar to analgesic drugs, celiac plexus neurolysis offers pain reduction without the significant adverse effects of opiates.<sup>2</sup> A multidisciplinary,

international guideline issued a strong recommendation based on moderate quality evidence for celiac plexus neurolysis as a treatment for pain associated with advanced pancreatic cancer.<sup>2</sup> Furthermore, a 2011 Cochrane review stated that celiac plexus block (neurolysis) significantly reduced opiate use and lowered pain compared to the control group.<sup>3</sup> A meta-analysis and systematic review demonstrated pain relief up to 53% to 80% of the time for the pooled proportion of patients with pancreatic cancer treated with EUS-guided celiac plexus neurolysis.<sup>53</sup>

The optimal timing of celiac plexus neurolysis for pain due to pancreatic cancer is not known.<sup>2</sup> Advocates of an earlier approach argue that pain is more effectively addressed by neurolysis when treated earlier, and opiate-related side effects may also be reduced compared to later treatment. However, the effects of celiac plexus neurolysis diminish over time, which would leave a patient with fewer options as the cancer progresses and pain becomes more severe. Repeat celiac plexus neurolysis for pain due to pancreatic cancer is effective only about 30% of the time and is not recommended.<sup>2,17</sup>

#### *Celiac Plexus Nerve Block/Neurolysis for Chronic Pancreatitis*

Celiac plexus blockade is an option for pain relief in patients with refractory pain due to chronic pancreatitis and a non-dilated pancreatic duct. Advantages of celiac plexus blockade include that a single treatment can potentially provide pain reduction or relief, may reduce, or eliminate the need for oral analgesia, and can be performed quickly and repeated as needed. However, it is unclear which patients will derive the most benefit and the pain relief is transient, lasting for three to six months.<sup>24</sup>

The American College of Gastroenterology suggests considering celiac plexus block for treatment of pain in chronic pancreatitis (conditional recommendation, very low quality of evidence) noting that celiac plexus blockade represents a relatively low-risk, opioid-free method to reduce refractory pain in certain patients with chronic pancreatitis.<sup>41</sup>

#### *Intercostal Nerve Blocks*

Intermittent intercostal nerve blocks can be used to control pain in the chest and upper abdomen, such as pain associated with rib fractures or chronic pain due to post herpetic neuralgia. Intercostal nerve blocks can be performed using anatomic landmarks or with ultrasound guidance, which can be used to minimize the chance of intravascular injection and pneumothorax and to increase reliable dermatomal coverage.<sup>4,8</sup>

For isolated injuries, such as single rib fracture, nonsteroidal anti-inflammatory drugs with or without opioids would be the initial treatment. For more severe injuries, particularly if ventilation is compromised, intercostal nerve blocks may be needed. For patients with multiple rib fractures, there is a need to perform the procedure at multiple intercostal levels. Repeated blockade may be needed for prolonged relief upon return of pain and/or deterioration in functional status. For repeat blocks or other interventions, patient must have been responsive to prior interventions with improvement in physical and functional status.<sup>5,8</sup>

Regional anesthesia plays an important role in thoracic surgery, particularly with regard to post-operative pain control. The first choice of regional anesthesia for thoracic surgery is epidural

analgesia or thoracic paravertebral block. In general, the analgesic efficiencies of both these types of anesthesia are equivalent; however, thoracic paravertebral block has some advantages over epidural analgesia, including fewer complications. When these two blocks are contraindicated, intercostal nerve block or interpleural block should be considered.<sup>6,7</sup>

#### *Genicular Nerve Blocks and Radiofrequency Neurotomy*

The genicular nerve is a sensory nerve that surrounds the knee and provides innervation for the joint. Genicular nerve blocks, neurolysis and radiofrequency neurotomy are emerging interventions for knee pain. The limited evidence regarding genicular nerve blocks for determining appropriateness of treatment with genicular radiofrequency ablation has reached conflicting results.<sup>9,10,18</sup> A few small studies suggest that genicular radiofrequency neurotomy may be effective for relief of pain, but further research is needed to establish safety and efficacy.  
11-15

#### *Peripheral/Ganglion Nerve Blocks*

Peripheral nerve blocks (PNB) are widely used for surgical anesthesia as well as for both postoperative and nonsurgical analgesia. Indications for PNBs are diverse and vary widely. Blocks are often used to avoid the effects of alternative anesthetics or analgesics. The most common rationale for their use is to avoid side effects and complications of general anesthesia, particularly respiratory-related effects, and to provide analgesia while minimizing opioid use.<sup>37</sup>

Chronic pain can be treated with a number of pharmacologic and nonpharmacologic therapies which generally fall into six major categories: pharmacologic, physical medicine, behavioral medicine neuromodulation, interventional and surgical approaches.<sup>33</sup> Optimal outcomes result from multiple approaches.<sup>33,50</sup> Interventional approaches, which typically attempt to target the presumed pain generators, may play a complementary role to other strategies (e.g., rehabilitation and appropriate pharmacotherapy.) The best candidates for interventional management have persistent focal pain of shorter duration, appropriate expectations, and well-managed psychosocial distress.<sup>33</sup>

Cancer pain can be caused by complex interactions among cancer cells, the peripheral and central nervous systems, and the immune system. Peripheral pain receptors may become activated, sensitized, or injured with certain cancers. Neuropathic pain may arise from nerve tissue damage and cancer patients may experience mild to severe pain. At least 15% will experience no relief or have severe adverse effects from interventions to address their pain. Nerve blocks or other interventional procedures may be appropriate as part of a comprehensive pain management program.<sup>34, 35</sup>

#### *Peripheral Nerve Blocks for Diagnosis and Treatment of Post-Herniorrhaphy Groin Pain*

Persistent pain following inguinal hernia surgery is relatively common and a comprehensive pain management program is recommended. A prospective study, including elective primary open hernia repairs, found persistent pain occurred in 16.5 to 16.1 percent of patients at six months and five years.<sup>36</sup> Acute pain persisting more than eight weeks is most likely neuropathic due to primary or secondary nerve injuries. Post-herniorrhaphy neuralgia should be suspected if pain persists beyond six to eight weeks. These patients should undergo imaging to exclude

nonneuropathic causes. Patients with positive response to initial nerve block can be treated every one to three weeks until pain relief is sustained. Those who have a positive response initially, but the pain returns, may require groin nerve sacrifice via percutaneous nerve ablation or surgical neurectomy.<sup>36</sup>

#### *Peripheral Nerve Blocks for Prevention or Treatment of Headaches*

Peripheral nerve blocks have been proposed as a treatment for migraines in pregnancy and refractory migraines. However, evidence is limited to support this indication. In a series of 13 birthing individuals with migraine refractory to medication, injection of local anesthetic into one or more peripherals nerve resulted in elimination of pain in seven individuals, pain reduction in two and no response in four. Larger studies are necessary to better define the efficacy of this approach.<sup>31</sup>

#### *Peripheral Nerve Blocks for Prevention or Treatment of Trigeminal Neuralgia*

Compression of the trigeminal nerve root is the main mechanism of trigeminal neuralgia, but brainstem lesions account for a small proportion of cases. Initial treatment of most patients with trigeminal neuralgia is pharmacologic therapy. For patients with trigeminal neuralgia refractory to medical therapy, it is reasonable to discuss options for surgical therapy (e.g., microvascular decompression, various types of rhizotomy, or gamma knife radiosurgery.) The decision to have surgery and the choice among surgical options will be influenced by individual circumstances including patient preference, adverse effect profile of the available techniques, and expertise of the local center.<sup>42</sup> There is insufficient evidence in the published peer-reviewed literature to support the use of peripheral nerve blocks for the treatment of trigeminal neuralgia.<sup>63</sup>

#### *Intraosseous Radiofrequency Nerve Ablation of Basivertebral Nerve*

Basivertebral nerve radiofrequency ablation has been developed for the treatment of chronic low back pain thought to originate from the vertebral body endplates.<sup>43</sup> The Intracept Intraosseous Nerve Ablation System, Relivant Medsystems, Inc. is approved by the U.S. Food and Drug Administration (FDA) and intended to be used in conjunction with radiofrequency generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae. Its purpose is to relieve chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is also accompanied by features consistent with Type 1 or Type 2 Modic changes on an MRI [e.g., inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic change), and changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change)].<sup>49</sup>

Current studies report pain relief and improvement in function and quality of life after treatment; however, most are company-sponsored, limited in size and are of generally poor or fair quality. A review of full-text clinical practice guidelines and position statements offers weak support for the Intracept Intraosseous Nerve Ablation for chronic low back pain of suspected vertebrogenic origin. The North American Spine Society's (NASS) recommendations regarding basivertebral nerve ablation for low back pain are not supported by the American Association of Neurological Surgeons (AANS), Congress of Neurological Surgeons (CNS), and the AANS/CNS Joint

Section on Disorders of the Spine and Peripheral Nerves (DSPN) due to NASS's overly broad indications and contradictory clinical data.<sup>61, 62</sup> Long-term non-industry-funded prospective trials should be pursued to confirm the results of currently published clinical studies.<sup>44</sup>

### **Coding Implications**

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2025, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only and may not support medical necessity. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| <b>CPT® Codes</b> | <b>Description</b>                                                                                                                                     |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| 64400             | Injection(s), anesthetic agent(s) and/or steroid; trigeminal nerve, each branch (ie, ophthalmic, maxillary, mandibular)                                |
| 64405             | Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve                                                                              |
| 64408             | Injection(s), anesthetic agent(s) and/or steroid; vagus nerve                                                                                          |
| 64415             | Injection(s), anesthetic agent(s) and/or steroid; brachial plexus, including imaging guidance, when performed                                          |
| 64417             | Injection(s), anesthetic agent(s) and/or steroid; axillary nerve, including imaging guidance, when performed                                           |
| 64418             | Injection(s), anesthetic agent(s) and/or steroid; suprascapular nerve                                                                                  |
| 64420             | Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, single level                                                                      |
| 64421             | Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, each additional level (list separately in addition to code for primary procedure) |
| 64425             | Injection(s), anesthetic agent(s) and/or steroid; ilioinguinal, iliohypogastric nerves                                                                 |
| 64430             | Injection(s), anesthetic agent(s) and/or steroid; pudendal nerve                                                                                       |
| 64435             | Injection(s), anesthetic agent(s) and/or steroid; paracervical (uterine) nerve                                                                         |
| 64445             | Injection(s), anesthetic agent(s) and/or steroid; sciatic nerve, including imaging guidance, when performed                                            |
| 64447             | Injection(s), anesthetic agent(s) and/or steroid; femoral nerve, including imaging guidance, when performed                                            |
| 64450             | Injection(s), anesthetic agent(s) and/or steroid; other peripheral nerve or branch                                                                     |
| 64454             | Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed                                 |
| 64505             | Injection, anesthetic agent; sphenopalatine ganglion                                                                                                   |
| 64510             | Injection, anesthetic agent; stellate ganglion (cervical sympathetic)                                                                                  |
| 64517             | Injection, anesthetic agent; superior hypogastric plexus                                                                                               |
| 64520             | Injection, anesthetic agent; lumbar or thoracic (paravertebral sympathetic)                                                                            |
| 64530             | Injection, anesthetic agent; celiac plexus, with or without radiologic monitoring                                                                      |

| CPT® Codes | Description                                                                                                                                                                                           |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 64600      | Destruction by neurolytic agent, trigeminal nerve; supraorbital, infraorbital, mental, or inferior alveolar branch                                                                                    |
| 64605      | Destruction by neurolytic agent, trigeminal nerve; second and third division branches at foramen ovale                                                                                                |
| 64610      | Destruction by neurolytic agent, trigeminal nerve; second and third division branches at foramen ovale under radiologic monitoring                                                                    |
| 64620      | Destruction by neurolytic agent, intercostal nerve                                                                                                                                                    |
| 64624      | Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed                                                                                                  |
| 64628      | Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral                                                                   |
| 64629      | Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure) |
| 64640      | Destruction by neurolytic agent; other peripheral nerve or branch                                                                                                                                     |
| 64680      | Destruction by neurolytic agent, with or without radiologic monitoring; celiac plexus                                                                                                                 |
| 64999      | Unlisted procedure, nervous system                                                                                                                                                                    |

| Reviews, Revisions, and Approvals                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Revision Date | Approval Date | Effective Date |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------------|----------------|
| Converted corporate to local policy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 12/01/20      |               |                |
| Annual review. Added refractory chronic pancreatitis as an indication for celiac plexus block to section III and updated background accordingly. Added ICD -10 codes K86.0 and K86.1 to support coverage criteria. Changed “Experimental/investigational” language in section V. and VI.E. to “insufficient evidence to support...”. Under section VI, moved “Note” for visibility. Added insufficient evidence to support peripheral nerve block for treatment of trigeminal neuralgia to VI.D, removed G50.0 from list of ICD 10 codes that support coverage criteria and updated background accordingly. References reviewed, reformatted and updated. Changed “review date” in the header to “date of last revision” and “date” in the revision log header to “revision date.” Reviewed by specialist. Added note in section VI to state: If administered as part of a surgery or other procedure, coding for peripheral/ganglion nerve blocks should follow proper coding practices and would not be subject to prior authorization or payment separately from the procedure. Revised policy title from “Nerve Blocks for Pain Management” to “Nerve Blocks and Neurolysis for Pain Management.” Added VII. Insufficient evidence to determine the safety and effectiveness of |               |               |                |

| Reviews, Revisions, and Approvals                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Revision Date | Approval Date | Effective Date |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------------|----------------|
| intraosseous radiofrequency nerve ablation of basivertebral nerve. Updated background and references accordingly. Added “as effectiveness has not been established” to I. C. Background updated. Reworded some extraneous language with no clinical significance.                                                                                                                                                                                                                                              |               |               |                |
| Annual review completed. Examples added to I.B.1. and III.B.2. Minor rewording with no clinical significance. Background updated. Added CPT codes 64628. ICD-10 Diagnosis code table removed. References reviewed and updated. External specialist reviewed.                                                                                                                                                                                                                                                   | 09/23         | 11/27/23      | 12/27/23       |
| Annual review completed. Minor rewording with no clinical significance. References reviewed and updated. Updated Cpt Code table                                                                                                                                                                                                                                                                                                                                                                                | 5/24          | 7/16/24       | 8/16/24        |
| Annual review. Added note in Description to refer to CP.MP.171 Facet Joint Interventions for facet joint injections and radiofrequency neurotomy. Added clarifying language to Criteria I.A.2. Updated Criteria II.A.1.c. to include application of lidocaine and minor grammatical change made. Grammatical update made in Criteria II.B.1. for clarity. Grammatical update made in Criteria VI.B.2.b. for clarity. References reviewed and updated. Reviewed by internal specialist and external specialist. | 03/25         | 5/20/25       | 6/19/25        |
| Annual review. Description updated with no clinical significance. Table of Contents updated. Background updated with additional information regarding basivertebral nerve radiofrequency ablation added to appropriate section. Coding reviewed and updated. Added CPT code 64629. References reviewed and updated.                                                                                                                                                                                            | 04/26         | 7/7/26        | 8/7/26         |

## References

1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018;38(1):1 to 211. doi:10.1177/0333102417738202
2. Drewes AM, Campbell CM, Ceyhan GO, et al. Pain in pancreatic ductal adenocarcinoma: A multidisciplinary, International guideline for optimized management. *Pancreatology*. 2018;18(4):446 to 457. doi: 10.1016/j.pan.2018.04.008
3. Arcidiacono PG, Calori G, Carrara S, McNicol ED, Testoni PA. Celiac plexus block for pancreatic cancer pain in adults. *Cochrane Database Syst Rev*.2011;2011(3):CD007519. Published 2011 Mar 16. doi:10.1002/14651858.CD007519.pub2
4. Bashir MM, Shahzad MA, Yousaf MN, Khan BA, Khan FA. Comparison of postoperative pain relief by intercostal block between pre-rib harvest and post-rib harvest groups. *J College Physicians Surg Pak*. 2014;24(1):43 to 46.
5. Sarani B. Inpatient management of traumatic rib fractures and flail chest in adults. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated March 27, 2025. Accessed January 14, 2026.

6. Hwang EG, Lee Y. Effectiveness of intercostal nerve block for management of pain in rib fracture patients. *Exerc Rehabil*. 2014;10(4):241 to 244. doi:10.12965/jer.140137
7. Morimoto Y. Regional anesthesia for thoracic surgery. *Anesthesia Pain and Intensive Care*. 2015;19:352 to 356.
8. Rice DC, Cata JP, Mena GE, Rodriguez-Restrepo A, Correa AM, Mehran RJ. Posterior Intercostal Nerve Block With Liposomal Bupivacaine: An Alternative to Thoracic Epidural Analgesia. *Ann Thorac Surg*. 2015;99(6):1953 to 1960. doi:10.1016/j.athoracsur.2015.02.074
9. Health Technology Assessment. Genicular Nerve Block for the Treatment of Knee Osteoarthritis. Hayes. [www.hayesinc.com](http://www.hayesinc.com). Published December 7, 2023 (annual review December 4, 2025.) Accessed January 14, 2026.
10. McCormick ZL, Reddy R, Korn M, et al. A Prospective Randomized Trial of Prognostic Genicular Nerve Blocks to Determine the Predictive Value for the Outcome of Cooled Radiofrequency Ablation for Chronic Knee Pain Due to Osteoarthritis. *Pain Med*. 2018;19(8):1628 to 1638. doi:10.1093/pm/pnx286
11. Kesikburun S, YaSar E, Uran A, Adiguzel E, Yimaz B. Ultrasound-guided genicular nerve pulsed radiofrequency treatment for painful knee osteoarthritis: a preliminary report. *Pain Physician* 2016;19(5):E751 to E759.
12. Qudsi-Sinclair S, Borrás-Rubio E, Abellan-Guillén JF, Padilla Del Rey ML, Ruiz-Merino G. A comparison of genicular nerve treatment using either radiofrequency or analgesic block with corticosteroid for pain after a total knee arthroplasty: a double-blind, randomized clinical study. *Pain Pract*. 2017;17(5):578 to 588. doi:10.1111/papr.12481
13. Ahmed A, Arora D. Ultrasound-guided radiofrequency ablation of genicular nerves of knee for relief of intractable pain from knee osteoarthritis: a case series. *Br J Pain*. 2018;12(3):145 to 154. doi: 10.1177/2049463717730433
14. Kim DH, Choi SS, Yoon SH, et al. Ultrasound-guided genicular nerve block for knee osteoarthritis: a double-blind, randomized controlled trial of local anesthetic alone or in combination with corticosteroid. *Pain Physician*. 2018;21(1):41 to 52.
15. Choi WJ, Hwang SJ, Song JG, et al. Radiofrequency treatment relieves chronic knee osteoarthritis pain: a double-blind randomized controlled trial. *Pain*. 2011;152(3):481 to 487. doi: 10.1016/j.pain.2010.09.029
16. Kucera TJ, Boezaart AP. Regional anesthesia does not consistently block ischemic pain: two further cases and a review of the literature. *Pain Med*. 2014;15(2):316 to 319. doi:10.1111/pme.12235
17. McGreevy K, Hurley RW, Erdek MA, Aner MM, Li S, Cohen SP. The effectiveness of repeat celiac plexus neurolysis for pancreatic cancer: a pilot study. *Pain Pract*. 2013;13: 89 to 95. doi:10.1111/j.1533-2500.2012.00557.x
18. Gonzalez Sotelo V, Maculée F, Minguell J, Bergé R, Franco C, Sala-Blanch X... Ultrasound-guided genicular nerve block for pain control after total knee replacement: preliminary case series and technical note. *Rev Esp Anesthesiol Reanim*. 2017;64(10):568 to 576. doi:10.1016/j.redar.2017.04.001
19. Garza I. Occipital neuralgia. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated March 3, 2025. Accessed January 14, 2026.
20. Rosenblatt MA, Lai Y. Scalp block and cervical plexus block techniques. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated June 13, 2024. Accessed January 14, 2026.

21. Abdi S. Complex regional pain syndrome in adults: pathogenesis, clinical manifestations, and diagnosis. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated September 3, 2024. Accessed January 14, 2026.
22. Abdi S. Complex regional pain syndrome in adults: treatment, prognosis, and prevention. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated December 17, 2025. Accessed January 14, 2026.
23. Fernandez-del Castillo C, Jimenez RE, Murphy JE. Supportive care of the patient with locally advanced or metastatic exocrine pancreatic cancer. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated December 17, 2025. Accessed January 14, 2026.
24. Freedman SD, Forsmark CE. Chronic pancreatitis: management. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated March 4, 2024. Accessed January 14, 2026.
25. Evidence Analysis Research Brief. Local injection therapy for cervicogenic headache and occipital neuralgia. Hayes. [www.hayesinc.com](http://www.hayesinc.com). Published February 2, 2023. Accessed January 14, 2026.
26. Soloman M, Mekhail MN, Mekhail N. Radiofrequency treatment in chronic pain. *Expert Rev Neurother*. 2010;10(3):469 to 474. doi:10.1586/ern.09.153
27. Copenhagen DJ, Pritzlaff SG, et al. Interventional therapies for chronic pain. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated September 22, 2025. Accessed January 14, 2026.
28. Lavu H, Lengel HB, Sell NM, et al. A prospective, randomized, double-blind, placebo controlled trial on the efficacy of ethanol celiac plexus neurolysis in patients with operable pancreatic and periampullary adenocarcinoma. *J Am Coll Surg*. 2015;220(4):497 to 508. doi: 10.1016/j.jamcollsurg.2014.12.013
29. Wyse JM, Carone M, Paquin SC, Usatii M, Sahai AV. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. *J Clin Oncol*. 2011;29(26):3541 to 3546. doi:10.1200/JCO.2010.32.2750
30. American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. *Anesthesiology* 2010;112(4):810 to 833. doi: 10.1097/ALN.0b013e3181c43103
31. Lee MJ, Guinn D, Hickenbottom S. Headache during pregnancy and postpartum. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated November 18, 2024. Accessed January 14, 2026.
32. Matharu MS, Cohen AS. Short-lasting unilateral neuralgiform headache attacks: treatment and prognosis. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated August 14, 2024. Accessed January 14, 2026.
33. Tauben D, Stacey BR. Approach to the management of chronic non-cancer pain in adults. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated January 12, 2026. Accessed January 14, 2026.
34. Smith TJ, Saiki CB. Cancer pain management. *Mayo Clin Proc*. 2015;90(10):1428 to 1439. doi: 10.1016/j.mayocp.2015.08.009
35. Chambers WA. Nerve blocks in palliative care. *Br J Anaesth*. 2008; P 101(1):95 to 100. doi:10.1093/bja/aen105
36. Bonwich, JB. Post-herniorrhaphy groin pain. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated March 18, 2024. Accessed January 14, 2026.
37. Jeng, CL, Rosenblatt, MA. Overview of peripheral nerve blocks. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated July 30, 2025. Accessed January 14, 2026.

38. Phillips K, Schur PH. Management of isolated musculoskeletal chest pain. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated February 26, 2025. Accessed January 14, 2026.
39. Wiersema MJ, Saumoy M. Endoscopic ultrasound-guided celiac plexus interventions for pain related to pancreatic disease. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated May 28, 2025. Accessed January 14, 2026.
40. Health Technology Assessment. Radiofrequency nerve ablation for the management of osteoarthritis of the knee. Hayes. [www.hayesinc.com](http://www.hayesinc.com). Published December 22, 2020 (annual review December 28, 2023). Accessed January 14, 2026.
41. Gardner TB, Adler DG, Forsmark CE, Sauer BG, Taylor JR, Whitcomb DC. ACG clinical guideline: chronic pancreatitis. *Am J Gastroenterol*. 2020;115(3):322 to 339. doi:10.14309/ajg.0000000000000535
42. Ho CC, Khan SA, Whealy MA. Trigeminal neuralgia. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated May 8, 2025. Accessed January 14, 2026.
43. Michalik A, Conger A, Smuck M, Maus TP, McCormick ZL. Intraosseous basivertebral nerve radiofrequency ablation for the treatment of vertebral body endplate low back pain: current evidence and future directions. *Pain Med*. 2021;22(Suppl 1):S24 to S30. doi:10.1093/pm/pnab117
44. Evolving Evidence Review. Intracept intraosseous nerve ablation system (relievent medsystems inc.) for treatment of adults with low back pain. Hayes. [www.hayesinc.com](http://www.hayesinc.com). Updated November 20, 2025. Accessed January 14, 2026.
45. Fischgrund JS, Rhyne A, Franke J, et al. Intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: a prospective randomized double-blind sham-controlled multi-center study. *Eur Spine J*. 2018;27(5):1146 to 1156. doi:10.1007/s00586-018-5496-1
46. Fischgrund JS, Rhyne A, Macadaeg K, et al. Long-term outcomes following intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 5-year treatment arm results from a prospective randomized double-blind sham-controlled multi-center study. *Eur Spine J*. 2020;29(8):1925 to 1934. doi:10.1007/s00586-020-06448-x
47. Khalil JG, Smuck M, Koreckij T, et al. A prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain. *Spine J*. 2019;19(10):1620 to 1632. doi:10.1016/j.spinee.20
48. Fischgrund JS, Rhyne A, Franke J, et al. Intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: a prospective randomized double-blind sham-controlled multi-center study. *Eur Spine J*. 2018;27(5):1146-1156. doi:10.1007/s00586-018-5496-1
49. United States Food and Drug Administration. 510(k) Premarket Notification. Intracept Intraosseous Nerve Ablation System (RF Probe), Intracept Intraosseous Nerve Ablation System (Access Instruments), Relievent RF Generator. Food and Drug Administration Center for Devices and Radiological Health Web site. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf19/K190504.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf19/K190504.pdf). Published May 3, 2019. Accessed January 14, 2026.
50. Local coverage determination: peripheral nerve blocks (L36850). Centers for Medicare and Medicaid Services Website. <https://www.cms.gov/medicare-coverage-database/search.aspx>. Published May 1, 2017 (revised November 11, 2019). Accessed January 14, 2026.
51. Local coverage determination: thermal destruction of the intraosseous basivertebral nerve (BVN) for vertebrogenic lower back pain (L39420). Centers for Medicare and Medicaid

- Services Website. <https://www.cms.gov/medicare-coverage-database/search.aspx>. Published March 5, 2023. Accessed January 14, 2026.
52. Ebied AM, Nguyen DT, Dang T. Evaluation of occipital nerve blocks for acute pain relief of migraines. *J Clin Pharmacol*. 2020;60(3):378 to 383. doi:10.1002/jcph.1528
53. Kerdsirichairat T, Shin EJ. Endoscopic ultrasound guided interventions in the management of pancreatic cancer. *World J Gastrointest Endosc*. 2022;14(4):191 to 204. doi:10.4253/wjge.v14.i4.191
54. Pan W, Peng J, Elmofty D. Occipital Neuralgia. *Curr Pain Headache Rep*. 2021;25(9):61. Published 2021 Jul 21. doi:10.1007/s11916-021-00972-1
55. Aman MM, Mahmoud A, Deer T, et al. The American Society of Pain and Neuroscience (ASPN) Best Practices and Guidelines for the Interventional Management of Cancer-Associated Pain. *J Pain Res*. 2021;14:2139 to 2164. Published 2021 Jul 16. doi:10.2147/JPR.S315585
56. Filippiadis DK, Tselikas L, Tsitskari M, Kelekis A, de Baere T, Ryan AG. Percutaneous Neurolysis for Pain Management in Oncological Patients. *Cardiovasc Intervent Radiol*. 2019;42(6):791 to 799. doi:10.1007/s00270-019-02185-x
57. Evidence Analysis Research Brief. Greater occipital nerve block for treatment of occipital neuralgia. Hayes. [www.hayesinc.com](http://www.hayesinc.com). Published July 11, 2023. Accessed January 14, 2026.
58. Rosenblatt MA, Lai Y. Thoracic nerve block techniques. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated April 12, 2024. Accessed January 14, 2026.
59. Local coverage article: peripheral nerve blocks (A57788). Centers for Medicare and Medicaid Services Web site. <http://www.cms.hhs.gov/mcd/search.asp>. Published October 3, 2018 (revised October 30, 2025). Accessed January 14, 2026.
60. Local coverage determination: peripheral nerve blocks (L33933). Centers for Medicare and Medicaid Services Web site. <http://www.cms.hhs.gov/mcd/search.asp>. Published October 1, 2015 (revised January 8, 2019). Accessed January 14, 2026.
61. North American Spine Society. NASS coverage recommendations: basivertebral nerve ablation. <https://www.spine.org/Product-Details?productid=%7B0113E751-F070-ED11-9562-00224820E810%7D>. Published July 2, 2021. Accessed January 21, 2026.
62. Congress of Neurological Surgeons. Neurosurgery comments on NASS Draft Coverage Policy for basivertebral nerve ablation 06.01.22. <https://www.cns.org/advocacy/legislative-affairs-detail/neurosurgery-comments-on-nass-draft-coverage-polic>. Published June 1, 2022. Accessed January 21, 2026.
63. Evidence analysis brief: trigeminal nerve block for treatment of trigeminal neuralgia. Hayes. [www.hayesinc.com](http://www.hayesinc.com). Published December 10, 2025. Accessed January 21, 2026.

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing

this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of member/enrollees. This clinical policy is not intended to recommend treatment for member/enrollees. Member/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, member/enrollees, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

©2026 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.